Evidence map›Paper›PMID 36923952›Full record

ArticleMolecular therapy. Nucleic acids2023

Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation.

Mengxue Zhang, Jing Li, Qingwei Wang, Go Urabe, Runze Tang, Yitao Huang, Jose Verdezoto Mosquera, K Craig Kent, Bowen Wang, Clint L Miller and 1 more

Open access · goldFull text read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Precision epigenetic therapies in oncology.Cancer metastasis reviews · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mengxue ZhangDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Jing LiDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Qingwei WangDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Go UrabeDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Runze TangDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Yitao HuangDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Jose Verdezoto MosqueraDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA 22908, USA.
K Craig KentDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Bowen WangDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Clint L MillerDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA 22908, USA.
Lian-Wang GuoDepartment of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
University of Virginia · US

Funding

Multimodal genetic regulatory architecture of coronary artery diseaseR01HL148239 · NHLBI · UNIVERSITY OF VIRGINIA · PI Clint L Miller · 2019 to 2026
$4.2M
Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular SurgeryR01HL143469 · NHLBI · UNIVERSITY OF VIRGINIA · PI GONG, SHAOQIN -, GUO, LIANWANG · 2018 to 2021
$2.4M
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstructionR01HL129785 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GONG, SHAOQIN -, GUO, LIANWANG · 2016 to 2019
$2.0M
BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular SurgeryR01HL133665 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GUO, LIANWANG · 2016 to 2019
$1.6M
EPISTATIC REGULATORY MECHANISMS OF CORONARY HEART DISEASE RISKR00HL125912 · NHLBI · UNIVERSITY OF VIRGINIA · PI MILLER, CLINT L · 2017 to 2019
$747k
Epistatic Regulatory Mechanisms of Coronary Heart Disease RiskK99HL125912 · NHLBI · STANFORD UNIVERSITY · PI MILLER, CLINT L · 2015 to 2016
$285k
NHLBI NIH HHS K99 HL125912NHLBI NIH HHS R00 HL125912NHLBI NIH HHS R01 HL129785NHLBI NIH HHS R01 HL133665NHLBI NIH HHS R01 HL143469NHLBI NIH HHS R01 HL148239
6 · The paper itself

Abstract

Epigenetically switched, proliferative vascular smooth muscle cells (SMCs) form neointima, engendering stenotic diseases. Histone-3 lysine-27 trimethylation (H3K27me3) and acetylation (H3K27ac) marks are associated with gene repression and activation, respectively. The polycomb protein embryonic ectoderm development (EED) reads H3K27me3 and also enhances its deposition, hence is a canonical gene repressor. However, herein we found an unexpected role for EED in activating the

Indexed as

BRD4 in p57 repressioncooperativity between EED and BRD4EED in Ccnd1 activationepigenetic readersMT: Oligonucleotides: Therapies and Applicationsneointimasmooth muscle cell proliferation

Identifiers

PMID36923952
PMCPMC10009644
OpenAlexW4321460245

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read38
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.